Lantheus Holdings, Inc. $LNTH Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 97.0% in the first quarter, HoldingsChannel reports. The institutional investor owned 7,704 shares of the medical equipment provider’s stock after selling 247,589 shares during the quarter. Pacer Advisors Inc.’s holdings in Lantheus were worth $584,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. M&T Bank Corp purchased a new stake in shares of Lantheus during the 4th quarter worth approximately $370,950,000. Farallon Capital Management LLC increased its stake in Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after purchasing an additional 1,950,252 shares in the last quarter. Reinhart Partners LLC. raised its holdings in Lantheus by 15.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock worth $103,990,000 after purchasing an additional 214,820 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Lantheus by 3.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after purchasing an additional 44,374 shares during the last quarter. Finally, Carmignac Gestion boosted its position in Lantheus by 18.4% during the first quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock worth $100,729,000 after purchasing an additional 206,000 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. William Blair set a $102.50 price objective on shares of Lantheus in a research note on Monday, August 3rd. Citizens Jmp restated a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. Leerink Partners set a $102.50 price target on shares of Lantheus in a report on Monday, August 3rd. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research report on Thursday, May 7th. Five research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $108.11.

Lantheus Price Performance

LNTH opened at $100.98 on Tuesday. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86. The company’s 50 day simple moving average is $104.17 and its 200 day simple moving average is $88.39. The stock has a market capitalization of $6.59 billion, a PE ratio of 24.39 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same quarter last year, the firm posted $1.57 earnings per share. Lantheus’s revenue was up 2.7% on a year-over-year basis. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 4.5 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.